P592 Efficacy of vedolizumab for induction and maintenance of clinical remission in ulcerative colitis: The UCLH experience

Abstract Background Vedolizumab is an α4β7 integrin antagonist which blocks gut-specific leucocyte migration. It is indicated for induction and maintenance of remission in moderate to severe ulcerative colitis (UC) and Crohn’s disease.1 The aim of this study was to characterise the use and efficacy...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Crohn's and colitis 2018-01, Vol.12 (supplement_1), p.S407-S408
Main Authors: Vinayaga-Pavan, M, Kumagai, T, Parisi, I, Barragry, J, Sundramoorthi, R, Whitley, L, Parker, H, Kettle, R, McCabrey, N, Steward, E, McCartney, S, Bloom, S, Vega, R, Mehta, S, Rahman, F
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Vedolizumab is an α4β7 integrin antagonist which blocks gut-specific leucocyte migration. It is indicated for induction and maintenance of remission in moderate to severe ulcerative colitis (UC) and Crohn’s disease.1 The aim of this study was to characterise the use and efficacy of vedolizumab in the induction and maintenance of remission in UC patients at University College London Hospital, a tertiary UK IBD centre. Methods A retrospective review of all UC patients initiated on vedolizumab from October 2015 to November 2016 was completed. A 52-week follow-up was completed on all patients. Patient characteristics and clinical review data with SCCAI score were collected. Clinical response was defined as a reduction of SCCAI to
ISSN:1873-9946
1876-4479
DOI:10.1093/ecco-jcc/jjx180.719